Complement Therapeutics Limited (CTx), a preclinical stage University of Manchester spinout, has recently closed a funding round from a leading European Life Sciences venture capital firm.

This Seed investment provides a 2 year runway, during which the company will seek to advance its portfolio of therapeutic assets.  The company is focussed on chronic diseases driven by the dysregulation of the complement system. This  includes two early stage ATMP therapeutic candidates with different modes of action. Additionally, CTx has developed a platform methodology allowing it to stratify patients based on their complement-activation profile. The platform will enable both patient selection for future clinical trials and possibility of making available a companion diagnostic for patients.

Built on the pioneering research carried out by its three founders at the University of Manchester, Prof Simon Clark, Dr Richard Unwin and Prof Paul Bishop, the CTx team has been working to fully realise the commercial potential of their developments with the guidance of the University of Manchester Innovation Factory, who helped the company with developing their business plan and strategy for the Seed investment in CTx.